Harrow (HROW) Q3 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2026 earnings summary
10 Nov, 2026Executive summary
Q3 revenue reached a record $99.3M, up 39% YoY and 41% QoQ, led by branded products; FY 2026 revenue guidance was reaffirmed at $350M–$365M.
FY 2026 Adjusted EBITDA outlook was reset to more than $40M, including more than $33M in Q4, versus prior guidance of $80M–$100M.
Financial highlights
Q3 GAAP net income was $9.8M versus $1.0M a year earlier; nine-month net loss was $35.1M versus $11.8M.
Q3 Adjusted EBITDA was $21.2M versus $22.8M YoY and a $1.2M loss in Q2; nine-month Adjusted EBITDA was $7.3M.
Q3 operating income was $11.5M versus $14.7M YoY; gross margin was 75%, level with a year earlier and up from 71% in Q2.
Nine-month revenue was $214.2M versus $183.2M; nine-month operating cash flow was negative $27.4M versus positive $35.5M.
Cash and equivalents totaled $75.3M at September 30, 2026; notes payable, net, was $292.7M.
Outlook and guidance
FY 2026 revenue guidance remains $350M–$365M; it implies Q4 revenue of $135.8M–$150.8M, up 37%–52% sequentially, and Q4 Adjusted EBITDA above $33M.
Q4 is expected to be the strongest quarter to date, supported by VEVYE and TRIESENCE growth, IHEEZO seasonality, BYOOVIZ traction and TYRVAYA's first revenue contribution.
TYRVAYA is expected to contribute more than $30M in 2027 revenue; about $20M of new annual operating expenses are expected, primarily for commercial and operational costs.
OPUVIZ is planned for U.S. launch in 2027; G-MELT potential launch is anticipated in 2028.
Latest events from Harrow
- Three growth brands, falling SG&A intensity, and launches planned through 2030.HROW
Jefferies Global Healthcare Conference - Long-term strategy targets $250M quarterly revenue by 2027, driven by G-MELT, IHEEZO, and VEVYE.HROW
12th Annual Cantor Fitzgerald Global Healthcare Conference - Q2 2026 revenue grew 11% YoY to $70.7M, with guidance reaffirmed and TYRVAYA acquisition announced.HROW
Q2 2026 - Accelerating growth driven by innovative eye care products and strong 2026 financial outlook.HROW
46th Annual William Blair Growth Stock Conference - Q1 2026 revenue was $44.2M, with strong product growth and improved liquidity.HROW
Q1 2026 - Key votes on directors, executive pay, and auditor set for June 2026 annual meeting.HROW
Proxy filing - Proxy covers director elections, say-on-pay, auditor ratification, and strong governance practices.HROW
Proxy filing - Double-digit growth and expanding ophthalmic launches drive strong future outlook.HROW
Leerink Global Healthcare Conference 2026 - Targets $250M+ quarterly revenue by Q4 2027, led by new launches and expanded access.HROW
Investor Day 2025